Lybalvi Now Available for Schizophrenia, Bipolar I Disorder
Lybalvi is an atypical antipsychotic comprised of samidorphan co-formulated with olanzapine in a single bilayer tablet.
Bipolar Disorders
Lybalvi Approved for Schizophrenia, Bipolar I Disorder
The approval was based on data from 27 clinical studies, including the phase 3 ENLIGHTEN-1 and ENLIGHTEN-2 studies.
Dexmedetomidine Oral Film Under Review for Agitation With Schizophrenia, Bipolar Disorder
In both trials, BXCL501 demonstrated statistically significant, rapid and durable improvements vs placebo across multiple agitation scales.
FDA Committees Vote on Novel Therapy for Schizophrenia, Bipolar I Disorder
ALKS 3831 is composed of samidorphan, a mu-opioid receptor antagonist, which is co-formulated with the established antipsychotic agent, olanzapine, in a single bilayer tablet.
Sleep, Cognition May Be Closely Linked in People With Bipolar Disorder
Sleep abnormalities and cognition in bipolar disorder may be related, and may affect cognition in this patient population.
Rest-Activity Pattern Disturbances Implicated in Borderline Personality Disorder
Among patients with borderline personality disorder, symptom severity was associated with less stability and lower relative amplitude. Impulsivity and mood instability were each negatively correlated with interdaily stability and relative amplitude.
Bipolar Disorder Associated With Increased Risk for Parkinson Disease
Compared with the general population, patients with bipolar disorder have an increased risk of developing idiopathic Parkinson disease.
Family History of Psychiatric Illness Increases Risk in Offspring
A family history of illness in prior generations may be related to an earlier age at onset of bipolar disease.
Using MRIs To Assess Suicide Risk in Young Bipolar Patients
There are specific differences found in the brains of those who attempt suicide and those who do not.
- Loading...
Loading...
Loading... 
Loading...